Background. Botswana introduced monovalent G1P[8] rotavirus vaccine (RV1) in July 2012, providing one of the first opportunities to assess the effectiveness of routine RV1 vaccination in a high-burden setting in Africa. We sought to determine the effectiveness of RV1 against rotavirus diarrhea hospitalization using a case-control evaluation.
Rotavirus remains a leading cause of vaccine-preventable mortality worldwide, accounting for an estimated 200 000 diarrheaassociated deaths annually among children <5 years of age [1] . African children are particularly hard hit by the virus, with >50% of rotavirus deaths occurring on the continent [2] . In Botswana, rotavirus has been detected in approximately 36% of children hospitalized for diarrhea [3] , and associated with an in-hospital case fatality rate of 2.8% [4] .
Two live attenuated oral rotavirus vaccines-RV5 (RotaTeq, Merck, Whitehouse Station, New Jersey) and RV1 (Rotarix, GSK Biologicals, Rixensart, Belgium)-are currently recommended by the World Health Organization (WHO) for introduction into national immunization programs in all countries globally [5] . In contrast to high-and middle-income nations in America and Europe [6] [7] [8] , where rotavirus vaccine efficacy has ranged from 83% to 95%, large randomized clinical trials of the 2 licensed vaccines demonstrated modest efficacy against severe rotavirus disease in sub-Saharan Africa (39%-61%) [9, 10] . In addition, clinical trials in Africa [9, 11] , as well as postlicensure assessments in low-income countries of Latin America [12, 13] , have shown a approximately 2-to 3-fold decline in protection in children aged ≥12 months, suggesting the possibility of waning immunity in resource-limited settings.
The underlying cause for the reduced performance of oral rotavirus vaccines observed in developing, high-mortality settings is poorly understood, but may reflect host factors that impair vaccine immunogenicity, such as interference from transplacental or breast milk antibodies, comorbidities (eg, human immunodeficiency virus [HIV] , undernutrition, environmental enteropathy), or high prevalence of enteric coinfections. The high amount of rotavirus strain diversity seen in poor settings may also play a role [14] .
In July 2012, Botswana's Ministry of Health introduced RV1 in all districts simultaneously, with 2 doses recommended at 2 and 3 months of age. With its relatively high levels of child mortality (53 deaths per 1000 live births), maternal HIV prevalence (estimated 38.5% prevalence among all women aged 25-49 years) [15] , and childhood malnutrition (7% moderate and severe wasting) [16] , and low rates of breastfeeding (20% exclusive breastfeeding <6 months) [16] , Botswana is a setting where assessing the "real world" effectiveness of rotavirus vaccination is crucial. The primary objective of this evaluation was to assess the association between RV1 and rotavirus diarrhea requiring hospitalization in Botswana.
METHODS

Setting
Botswana is an upper-to middle-income country in southern Africa with a gross national income per capita of $7770 [17] ; however, income inequality (Gini index >0.5) and poverty (21%) remain high [18] . The annual birth cohort is approximately 48 000 [17] .
From 4 June 2013 to 7 April 2015, we conducted active hospital-based surveillance for diarrhea in the emergency departments and pediatric wards of 4 hospitals in Botswana: 2 national referral hospitals (Princess Marina Hospital in Gaborone and Nyangabgwe Referral Hospital in Francistown), 1 district hospital (Letsholathebe II in Maun), and 1 primary hospital (Bobonong Primary Hospital in Bobonong). These hospitals are located in the eastern and north-central regions of the county, where 80% of Botswana's population lives.
Participants: Case Patients and Controls
Case patients and controls were enrolled at participating hospitals during diarrhea surveillance if they had either ≥3 episodes of diarrhea (looser than normal stools) or ≥2 episodes of emesis and any episodes of diarrhea within a 24-hour period, lasting <7 days. Children were excluded if they had hospital-acquired gastroenteritis (symptom onset ≥48 hours after admission or <7 days after discharge from a hospital). A case patient was defined as a child ≥4 months of age hospitalized for laboratoryconfirmed rotavirus diarrhea by enzyme immunoassay (EIA) who was age-eligible to receive rotavirus vaccination (born after 1 May 2012). A control was defined as a child ≥4 months of age hospitalized for rotavirus-negative diarrhea by EIA (ie, who tested negative for rotavirus) and who was age-eligible to receive rotavirus vaccination.
Data Collection
After written informed consent, guardians were interviewed face to face and Botswana child clinic cards were reviewed for information on demographics, birth weight, history of breastfeeding, the child's medical history, and socioeconomic factors. Data on clinical presentation, treatment, and outcomes were collected through parental interview, from the medical record, and from the hospital staff providing care. Anthropometric data (weight and length) were obtained during hospital stay.
Moderate or severe undernutrition was defined as a weightfor-length z score < −2 based on WHO growth standards. Rotavirus vaccination status was confirmed by review of child clinic cards, if available from the parents during enrollment. A photocopy or photograph of the vaccination portion of the card was obtained to corroborate with transcribed vaccination data. In Botswana, information on maternal HIV and child HIV testing is recorded in child clinic cards following national guidelines. We categorized a child as HIV unexposed if his/her mother had a documented negative dual rapid immunochromatographic HIV test during pregnancy, and as HIV exposed if his/her mother had a documented positive result. Based on documented results of HIV DNA polymerase chain reaction testing at age ≥6 weeks, or of dual rapid immunochromatographic HIV testing at age ≥18 months, HIV-exposed children were further categorized as either HIV infected, HIV uninfected, or unknown status.
Specimen Collection, Storage, and Laboratory Testing Bulk stool and rectal swab specimens were collected from enrolled children within 48 hours of admission. Specimens were stored at −70°C in the referral and district-level hospitals, and at −20°C in Bobonong, prior to transport at −20°C to the Botswana National Health Laboratory in Gaborone, where testing for rotavirus antigen using a commercially available EIA kit (Rotaclone, Meridian Bioscience, Inc) was performed according to manufacturer instructions. Rectal swab samples were tested if bulk stool was not available. In the Botswana National Health Laboratory, specimens were frozen at −70°C until shipped to the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, where rotavirus-positive specimens were genotyped to determine the strain [19] .
Sample Size and Data Analysis
The main objective of this study was to estimate the effectiveness of 2 doses of RV1 against rotavirus-associated hospitalization. Assuming a case-to-control ratio of 1:2 and vaccine coverage of 70%, we estimated that a total of 196 case patients would be needed to detect a vaccine effectiveness (VE) of at least 40% for our primary outcome, at a 2-sided 5% significance level, with 80% power.
Primary analyses assessed effectiveness of 2 doses (full series), 1 dose (partial series), and 1 or more doses (intention to vaccinate analysis) of RV1, vs no vaccination. To identify potential confounders for the association between rotavirus vaccination and subsequent rotavirus diarrhea, analyses were done to assess for differences in characteristics and indicators of socioeconomic status between case patients and controls. Differences in categorical data were assessed using MantelHaenszel χ 2 tests; continuous variables were assessed with the Wilcoxon rank-sum test.
We then compared the proportion vaccinated among case patients and controls. Case patients and controls were considered S162 • CID 2016:62 (Suppl 2) • Gastañaduy et al vaccinated with the corresponding number of doses (eg, 1 or 2) if the most recent dose was administered ≥14 days before the date of presentation. VE was calculated using only data from children with confirmed vaccination status, ensuring use of accurately ascertained vaccination information.
Multivariable logistic regression models were constructed to calculate the odds ratios (ORs) with 95% confidence intervals (CIs) of rotavirus vaccination in case patients vs controls. A priori, models were adjusted for age (in months), birth month/year, and hospital. Adjusting for time of birth and hospital in the base models is important because it controls for potential confounding due to variation in vaccination uptake from month to month and by geographic location, respectively. We assessed for additional confounding by including in the primary model variables with a P value <.20 in the bivariate analyses. Hierarchical backward elimination approach was used to select the covariates in the final model, retaining variables significant at P < .05, or if their inclusion changed the OR associated with our primary outcome by >10%.
Subgroup analyses were conducted to assess (1) the duration of protection after vaccination, by measuring effectiveness among children aged 4-11 months compared to those ≥12 months of age; (2) a potential gradient in protection against illness of varying severity, using a previously described 20-point clinical severity score (Vesikari scale) [20] ; (3) strain-specific protection (against the predominant rotavirus genotype); (4) the differences in protection between children exclusively breastfed and those not exclusively breastfed; (5) the effectiveness by HIV exposure status among HIV-uninfected children; and (6) for differences in protection between children with and without moderate or severe malnutrition. To assess for differences in the subgroup analyses, an interaction term was included between vaccine receipt and the corresponding variable (age category, feeding practice, HIV exposure, or undernutrition) in the regression models.
Adjusted VE was calculated as (1 -adjusted OR) × 100%. Statistical significance was designated as P < .05. Analyses were performed using SAS statistical software (version 9.3).
This evaluation was approved by the institutional review boards of the Botswana Ministry of Health, participating hospitals, the University of Pennsylvania, McMaster University, and the CDC.
RESULTS
A total of 667 children aged ≥4 months met the inclusion criteria and were of eligible age for vaccination. Of these, 57 (9%) were excluded, either because documentation of rotavirus vaccination was unobtainable (20 [3%]), because insufficient or no stool sample was available for testing (36 [5%] ), or both (1 [<1%] ). Of the remaining 610 children, 242 (40%) were rotavirus-positive case patients, and 368 (60%) were test-negative controls. Only 6% of children had testing performed on rectal swab samples. All children were hospitalized and 89% received intravenous hydration; 16 died in the hospital (5 case patients and 11 controls). Table 1 shows a comparison of characteristics between case patients and test-negative controls. No differences in demographic or socioeconomic variables were noted between the 2 groups.
Among case patients and test-negative controls, 18% (43/ 242) and 9% (29/368) were unvaccinated, respectively; 15% (37/242) and 14% (51/368) had received 1 dose of RV1; and 67% (162/242) and 78% (288/368) had received 2 doses of RV1. Effectiveness of 2 doses of RV1 against rotavirus diarrhea requiring hospitalization was 54% (95% CI, 23%-73%; Table 2 ). One dose of RV1 also provided significant protection of 48% (95% CI, 1%-72%). When stratifying by age, receipt of 2 doses of RV1 was similarly effective among children 4-11 months of age (VE, 52% [95% CI, 8%-75%]), compared with children ≥12 months of age (VE, 67% [95% CI, 8%-89%]) (P = .39; Table 2 ).
Among 138 case patients with complete clinical information on rotavirus severity, 42 (30%) were classified as mild to moderate (Vesikari score ≤10), 78 (57%) as severe (Vesikari score ≥11 and <15), and 18 (13%) as very severe (Vesikari score ≥15). There was a tendency of increased protection against rotavirus of higher severity. Two doses of RV1 provided protection of 53% (95% CI, 8%-76%) against rotavirus diarrhea with severity score ≥11, and 70% (95% CI, 1%-91%) against severity score ≥15 (Table 2) .
Strain characterization was conducted for 67% (162/242) of rotavirus-positive specimens. Among these, G2P [4] was the predominant strain, detected in 37% (60/162) of the samples. G1P [8] and G9P [8] were commonly detected, accounting for 26% and 22% of all characterized strains, respectively. The remaining 15% were sparsely detected strains (G1P [6] , G2P [6] ). Effectiveness of a full series of RV1 against rotavirus caused by G2P [4] was 59% (95% CI, 4%-83%).
No differences in the effectiveness of 2 doses of RV1 against rotavirus hospitalization were observed between children who were exclusively breastfed during the first 6 months of life (VE, 50% [95% CI, −12% to 78%]), compared to those who were not (VE, 51% [95% CI, −18% to 80%]) (P = .85 for the comparison; Table 3 ). HIV exposure and infection status was available for 70% (425/610) of enrolled children. The effectiveness of 2 doses of RV1 was similar in HIV-unexposed children (VE, 44% [95% CI, −34% to 76%]) compared to HIV-exposed but uninfected children (VE, 32% [95% CI, −121% to 79%]) (P = .80). Anthropometry was performed in 497 (81%) of the 610 enrolled children; of these, 81 (16%) were classified as having moderate undernutrition and 69 (14%) as having severe undernutrition. The effectiveness of 2 doses of RV1 was significantly higher in children with no undernutrition (VE, 75% [95% CI, 41%-89%]), compared to those with moderate or severe undernutrition (VE, −28% [95% CI, −309% to 60%]) (P = .02).
DISCUSSION
This is one of the first evaluations of the effectiveness of rotavirus vaccination during routine programmatic use in Africa, in a setting where a variety of host and environmental factors may alter vaccine performance. We demonstrate that a full series of RV1 provided approximately 54% protection against rotavirusassociated hospitalizations among children in Botswana, similar to the efficacy (49%-77%) and effectiveness (57%-64%) of RV1 in clinical trials and postlicensure evaluations conducted in South Africa and Malawi [10, 21, 22] . In addition, we show short-period protection (approximately 48%) from 1 dose of RV1 against severe rotavirus diarrhea, in a country where a substantial proportion of diarrhea deaths occur among infants <6 months of age [23] [24] [25] , and where many infants might not return to complete their vaccination. Even with an apparent lower VE in African settings, demonstration of a protective effect is encouraging, as it is in populations with a high baseline burden of severe rotavirus outcomes where vaccination offers its greatest life-saving benefits. Furthermore, we show that the magnitude of protection increased with severity of illness in this population, reaffirming the potential benefits of vaccination against severe diarrhea resulting in mortality. Although studies have shown that RV1 protects against a variety of rotavirus strains, waning immunity to partly or fully heterotypic strains (ie, strains that share either the G or P type components of the vaccine strain, or share neither component, respectively) may be of concern in poor settings where genotypic diversity is common [26] . We demonstrate robust effectiveness of RV1 in a setting where a range of homotypic and heterotypic strains circulated during the study period, as well as sustained protection through 2 years of life. This sustained protection is consistent with that seen in field effectiveness studies in Malawi [21] and South Africa [27] , and allays concerns of waning immunity in the region, where most rotavirus admissions occur among children <2 years of age [4] . Importantly, we show, for the first time in Africa, that RV1 is protective against the fully heterotypic G2P [4] , findings that are supportive of a recent evaluation in Latin America [28] . This study was not powered to assess the durability of protection against G2P [4] , however, and one evaluation in an impoverished setting in Brazil noted a decline in effectiveness of RV1 against G2P [4] in older children [29] .
Compared to children born to HIV-uninfected mothers (HIVunexposed children), HIV-exposed but uninfected infants have been shown to have higher infectious morbidity and mortality [30] , and are thus a key group that could benefit from rotavirus vaccination. Similar to a previous evaluation of RV1 in South Africa [22] , we observed comparable effectiveness among HIVunexposed and HIV-exposed but uninfected children. Although there is evidence suggesting that antibody responses to vaccines are more robust in HIV-exposed but uninfected children [31, 32] , an effect attributed to lower transplacental transmission of vaccine-specific antibodies, and RV1 has been shown to be immunogenic in HIV-infected children [33] , the functional relevance of these responses requires further evaluation [30] .
Higher titers of rotavirus neutralizing antibodies in the breast milk of women from developing countries have been posited to partly explain the lower efficacy of rotavirus vaccines in resource-poor settings [34, 35] , and led to studies assessing whether transient withholding of breastfeeding around the time of vaccination could improve immune responses. Three studies in resource-limited countries have now shown that brief abstention from breastfeeding before and after vaccination does not appear to improve immunogenicity to RV1 [27, 36, 37] . Our results are in agreement with clinical trials demonstrating that RV1 is similarly protective in breastfed and formula-fed infants in industrialized nations [38] , and support promotion of breastfeeding during routine administration of rotavirus vaccination.
Conflicting evidence is available on the impact of nutritional status on the efficacy of rotavirus vaccines in developing countries. One study found that undernourished Brazilian children were less protected from rotavirus by an earlier candidate rotavirus vaccine [39] , whereas a secondary analysis of Latin American trial data showed that RV1 efficacy was similar in well-nourished and malnourished children [40] . These studies were limited by the small numbers of moderately to severely undernourished children. We show evidence that malnutrition may interfere with the effectiveness of RV1 in Botswana. Because malnourished children are more prone to die of diarrhea [3, 4] , emphasis placed on collection of data evaluating the role of malnutrition on the efficacy of rotavirus vaccines is warranted. Several limitations should be considered. We included 4 hospitals with distinct levels of care located in the most inhabited regions of Botswana, but our results may not be generalizable to the rest of the country. For practical reasons, we employed an unmatched study design using diarrhea test-negative controls. Test-negative controls have been shown to be similar in baseline characteristics to case patients and have been used extensively in rotavirus VE studies [21, 22, 28] , allowing for comparability, and their use yields similar estimates of effectiveness as when using matched nondiarrhea hospital or community controls. HIV status among mothers and children was based on documentation on child clinic cards, which might have led to misclassification (eg, a mother infected late in pregnancy, or an infant infected through recent breastfeeding). However, any such misclassification would have been rare and likely equal in both case patients and controls. Finally, because there were too few outcomes for a robust statistical model, we could not assess for any possible confounding among HIV exposure, replacement feeding, and malnutrition, and further research is needed to untangle their relative impact on vaccine performance.
CONCLUSIONS
In summary, under conditions of routine use, 2 doses of RV1 conferred protection against rotavirus admissions in Botswana, a challenging setting with high prevalence of childhood mortality, maternal HIV, and malnutrition. The effectiveness of RV1 was sustained during the first and second years of life; the measure of protection increased with severity of illness; 1 dose was significantly protective; and RV1 was effective against a variety of circulating strains, including the fully heterotypic G2P [4] . Taken together, these findings provide compelling evidence of the public health value of rotavirus vaccination in an African setting, and of its potential to curb severe rotavirus infection where the burden of fatal disease is highest. As broader use of rotavirus vaccines continues in an increasing number of African nations, further efforts to understand the comparatively lower protection achieved by these vaccines in resource-limited settings is critical. 
